BACKGROUND: Marked interindividual differences in vulnerability to nicotine dependence exist, but factors underlying such differences are not well understood. The midbrain alpha4beta2* subtype of nicotinic acetylcholine receptors (nAChRs) has been implicated in mediation of the reinforcing effects of nicotine responsible for dependence. However, no study has been performed evaluating the impact of interindividual differences in midbrain nAChR levels on motivation to self-administer nicotine. METHODS: Baseline levels of alpha4beta2* nAChRs were measured using 2-[(18)F]fluoro-A-85380 (2-FA) and positron emission tomography (PET) in five squirrel monkeys. Motivation to self-administer nicotine (number of lever presses) was subsequently measured using a progressive-ratio (PR) schedule of reinforcement. RESULTS: Greater motivation to self-administer nicotine was associated with lower levels of midbrain nAChRs. CONCLUSIONS: The results suggest that level of expression of nAChRs is a contributing factor in the development of nicotine dependence. Similarly, it has been previously shown that low levels of dopamine D(2) receptors (DRD2) are associated with a higher preference for psychostimulant use in humans and nonhuman primates. Together, results from these PET studies of dopaminergic and nicotinic cholinergic transmission suggest that an inverse relationship between the availability of receptors that mediate reinforcement and the motivation to take drugs exists across different neurotransmitter systems.
BACKGROUND: Marked interindividual differences in vulnerability to nicotine dependence exist, but factors underlying such differences are not well understood. The midbrain alpha4beta2* subtype of nicotinic acetylcholine receptors (nAChRs) has been implicated in mediation of the reinforcing effects of nicotine responsible for dependence. However, no study has been performed evaluating the impact of interindividual differences in midbrain nAChR levels on motivation to self-administer nicotine. METHODS: Baseline levels of alpha4beta2* nAChRs were measured using 2-[(18)F]fluoro-A-85380 (2-FA) and positron emission tomography (PET) in five squirrel monkeys. Motivation to self-administer nicotine (number of lever presses) was subsequently measured using a progressive-ratio (PR) schedule of reinforcement. RESULTS: Greater motivation to self-administer nicotine was associated with lower levels of midbrain nAChRs. CONCLUSIONS: The results suggest that level of expression of nAChRs is a contributing factor in the development of nicotine dependence. Similarly, it has been previously shown that low levels of dopamine D(2) receptors (DRD2) are associated with a higher preference for psychostimulant use in humans and nonhuman primates. Together, results from these PET studies of dopaminergic and nicotinic cholinergic transmission suggest that an inverse relationship between the availability of receptors that mediate reinforcement and the motivation to take drugs exists across different neurotransmitter systems.
Authors: M R Picciotto; M Zoli; R Rimondini; C Léna; L M Marubio; E M Pich; K Fuxe; J P Changeux Journal: Nature Date: 1998-01-08 Impact factor: 49.962
Authors: Michael A Nader; Drake Morgan; H Donald Gage; Susan H Nader; Tonya L Calhoun; Nancy Buchheimer; Richard Ehrenkaufer; Robert H Mach Journal: Nat Neurosci Date: 2006-07-09 Impact factor: 24.884
Authors: Andrew R Tapper; Sheri L McKinney; Raad Nashmi; Johannes Schwarz; Purnima Deshpande; Cesar Labarca; Paul Whiteaker; Michael J Marks; Allan C Collins; Henry A Lester Journal: Science Date: 2004-11-05 Impact factor: 47.728
Authors: N D Volkow; G J Wang; J S Fowler; J Logan; S J Gatley; A Gifford; R Hitzemann; Y S Ding; N Pappas Journal: Am J Psychiatry Date: 1999-09 Impact factor: 18.112
Authors: A G Horti; U Scheffel; A O Koren; H T Ravert; W B Mathews; J L Musachio; P A Finley; E D London; R F Dannals Journal: Nucl Med Biol Date: 1998-10 Impact factor: 2.408
Authors: Bernard Le Foll; Svetlana I Chefer; Alane S Kimes; Dean Shumway; Steven R Goldberg; Elliot A Stein; Alexey G Mukhin Journal: J Nucl Med Date: 2007-08-17 Impact factor: 10.057
Authors: Jacob G Dubroff; Robert K Doot; Mary Falcone; Robert A Schnoll; Riju Ray; Rachel F Tyndale; Arthur L Brody; Catherine Hou; Alexander Schmitz; Caryn Lerman Journal: J Nucl Med Date: 2015-08-13 Impact factor: 10.057
Authors: Bernard Le Foll; Svetlana I Chefer; Alane S Kimes; Elliot A Stein; Steven R Goldberg; Alexey G Mukhin Journal: Psychopharmacology (Berl) Date: 2016-02-25 Impact factor: 4.530
Authors: Jack E Henningfield; Tracy T Smith; Bethea A Kleykamp; Reginald V Fant; Eric C Donny Journal: Psychopharmacology (Berl) Date: 2016-10-21 Impact factor: 4.530
Authors: Emily M Jutkiewicz; Emily A Brooks; Adam D Kynaston; Kenner C Rice; James H Woods Journal: J Pharmacol Exp Ther Date: 2011-07-05 Impact factor: 4.030